Merritt Fajt
Allergy & Immunology · Pittsburgh, PANPI 1104039783
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations.
Across 108 payments — averaging $92.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Sanofi$2K
- AstraZeneca$2K
- CSL Behring$1K
- Grifols USA, LLC$497
- Genentech USA, Inc.$466
- plus $2K from 12 others
What the payments were for
- Food & beverage$9,87099%
- Education$1371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 22 | $2,383 |
| Sanofi | 16 | $1,818 |
| AstraZeneca | 17 | $1,757 |
| CSL Behring | 27 | $1,331 |
| Grifols USA, LLC | 6 | $497 |
| Genentech USA, Inc. | 4 | $466 |
| Regeneron Healthcare Solutions, Inc. | 3 | $367 |
| Shire North American Group Inc | 2 | $232 |
| Alk-abello, Inc | 2 | $178 |
| Pharming Healthcare, Inc. | 1 | $129 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $125 |
| Incyte Corporation | 1 | $114 |
| Biocryst US Sales Co., LLC | 1 | $112 |
| Blueprint Medicines Corporation | 1 | $110 |
| AbbVie | 1 | $106 |
| Regeneron | 1 | $101 |
| Optinose US, Inc. | 1 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $83 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,008 in reported general payments places this provider in the 70th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 13 | $1,038,469 |
| XolairOmalizumab | 63 | $215,260 |
| XembifyImmune Globulin,gamma(Igg)klhw | 26 | $103,528 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $73,721 |
| Dupixent SyringeDupilumab | 13 | $46,722 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $26,054 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $23,831 |
| Spiriva RespimatTiotropium Bromide | 27 | $13,258 |
| Epinephrine | 27 | $6,553 |
| Cromolyn Sodium | 44 | $4,275 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $3,976 |
| Flunisolide | 72 | $3,277 |
| Levocetirizine Dihydrochloride | 188 | $2,996 |
| Montelukast Sodium | 179 | $2,874 |
| Azelastine Hcl | 132 | $2,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda | $1,331 | $1,038,46913 claims |
| Grifols USA, LLCXembify | $497 | $103,52826 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $83 | $73,72114 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $2,383 | $49,88462 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Pittsburgh
- Sergei BelenkyPittsburgh$775K
- Christine RauscherPittsburgh$52K
- Hey ChongPittsburgh$10K
- Drew WeissmanPhiladelphia$12.8M
- Eric SchenkelBethlehem$845K
- Timothy CraigHershey$564K
- Sandra GawchikUpland$390K
- Anthony RooklinGlen Mills$319K
- Corinna BowserNarberth$229K
- Shailen ShahCollegeville$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.